ABBOTT LABORATORIES ABT
NYSE · XNYS · stock
Chart by TradingView
5/9
Piotroski F — financial health
4.8
Altman Z″ — distress risk · safe
63.1%
Dividend payout · stretched
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $44.3B | $6.5B | — | $7.4B | $52.1B |
| 2024 | $42.0B | $13.4B | — | $6.4B | $47.9B |
| 2023 | $40.1B | $5.7B | — | $5.1B | $38.6B |
| 2022 | $43.7B | $6.9B | — | $7.8B | $36.9B |
| 2021 | $43.1B | $7.1B | — | $8.6B | $35.8B |
| 2020 | $34.6B | $4.5B | — | $5.7B | $33.0B |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 4.8 (safe)
- Working capital / assets 0.11
- Retained earnings / assets 0.574
- EBIT / assets 0.093
- Equity / liabilities 1.507
Source: SEC EDGAR filings · CIK 0000001800 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.